<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913117</url>
  </required_header>
  <id_info>
    <org_study_id>BB IND 18340</org_study_id>
    <nct_id>NCT03913117</nct_id>
  </id_info>
  <brief_title>Study of Treatment for HPV16+ ASC-US or LSIL</brief_title>
  <acronym>PVX-6</acronym>
  <official_title>Phase I Clinical Trial Assessing the Safety and Feasibility of Intramuscular pNGVL4aCRTE6E7L2 and TA-CIN Administration for the Treatment of Patients With Persistent HPV16+ ASC-US or LSIL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PapiVax Biotech, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PapiVax Biotech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein
      vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

        1. To determine the safety and feasibility of intra-muscular administration of
           pNGVL4aCRTE6E7L2 DNA vaccine in patients with persistent HPV16+ ASC-US/LSIL.

        2. To determine the appropriate intra-muscular injection dose of pNGVL4aCRTE6E7L2 DNA
           vaccine as determined by toxicity and immunogenicity for a subsequent phase II clinical
           trial.

        3. To determine the safety and feasibility of intra-muscular administration of
           pNGVL4aCRTE6E7L2 DNA vaccine prime, TA-CIN protein vaccine boost in patients with
           persistent HPV16+ ASC-US/LSIL.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 18, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and feasibility of pNGVL4aCRTE6E7L2 DNA vaccination</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the safety and feasibility of intra-muscular administration of pNGVL4aCRTE6E7L2 DNA vaccine in patients with persistent HPV16+ ASC-US/LSIL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose finding</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the appropriate intra-muscular injection dose of pNGVL4aCRTE6E7L2 DNA vaccine as determined by toxicity and immunogenicity for a subsequent phase II clinical trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and feasibility of PVX-6 vaccination</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the safety and feasibility of intra-muscular administration of pNGVL4aCRTE6E7L2 DNA vaccine prime, TA-CIN protein vaccine boost in patients with persistent HPV16+ ASC-US/LSIL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HPV16 antibody response</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the levels of circulating antibody specific for HPV-16 in the peripheral blood pre- and post-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV16 CD8 T cell response</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the levels of circulating HPV-16 E6- and E7-specific CD8+ T cells and T regulatory cells in the peripheral blood pre- and post-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV16 L2E7E6 T cell proliferative response</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the proliferative responses of peripheral blood mononucleocytes pre- and post-vaccination in response to stimulation by HPV16 E6, E7 and L2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of HPV16</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the presence of high risk HPV, and specifically HPV16 in cytologic specimens pre- and post-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytologic clearance</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate changes in the cytopathology of ectocervical and endocervical specimens taken pre- and post-vaccination</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ASC-US</condition>
  <condition>LSIL</condition>
  <arm_group>
    <arm_group_label>pNGVL4aCRTE6E7L2 0.3mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pNGVL4aCRTE6E7L2 1 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pNGVL4aCRTE6E7L2 3 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVX-6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0 and 4, and the TA-CIN protein is administered by intramuscular injection at week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pNGVL4aCRTE6E7L2</intervention_name>
    <description>Naked pNGVL4aCRTE6E7L2 DNA plasmid</description>
    <arm_group_label>PVX-6</arm_group_label>
    <arm_group_label>pNGVL4aCRTE6E7L2 0.3mg dose</arm_group_label>
    <arm_group_label>pNGVL4aCRTE6E7L2 1 mg dose</arm_group_label>
    <arm_group_label>pNGVL4aCRTE6E7L2 3 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TA-CIN</intervention_name>
    <description>TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.</description>
    <arm_group_label>PVX-6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with persistent (&gt;6 month period) ASC-US/LSIL determined by cervical cytology
             at study entry (ThinPrep with imaging)

          2. Patients whose cytologic samples are persistent (&gt;6 month period) HPV16+ by Roche
             Cobas 4800, Roche Linear Array HPV Genotyping test or other FDA-approved HPV
             genotyping test at study entry. Co-infections with HPV types other than HPV16 are
             permissible for study entry.

          3. Age ≥ 19 years

          4. Baseline Eastern Cooperative Oncology Group

          5. Patients must have adequate organ function at the time of enrollment as defined by the
             following parameters:

               -  White blood cell count &gt; 3,000

               -  Absolute lymphocyte number &gt; 500

               -  Absolute neutrophil count &gt; 1,000

               -  Platelets &gt; 90,000

               -  Hemoglobulin &gt; 9

               -  Total bilirubin &lt;3 X the institutional limit of normal

                    -  AST(SGOT)/ALT(SGPT) &lt;3 X the institutional limit of normal

                    -  Creatinine &lt; 2.5X the institutional limit of normal

          6. Women of child-bearing potential must agree to use two forms of contraception
             (hormonal and barrier) prior to study entry and for 3 months after study completion.

          7. Ability to understand and the willingness to sign a written informed consent document.

          8. Subject is able to adhere to the study visit schedule and other protocol requirements.

        Exclusion Criteria:

          1. Patients with ASC-US/LSIL determined by cervical cytology at study entry that are
             HPV16 negative.

          2. Histologic evidence of CIN2+

          3. Patients with a diagnosis of immunosuppression or prolonged, active use of
             immunosuppressive medications such as steroids.

          4. Prior vaccination with any HPV antigen (prophylactic or therapeutic).

          5. Patients who are receiving any other investigational agents within 28 days prior to
             the first dose.

          6. Patients with an uncontrolled intercurrent illness including, but not limited to,
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          7. Patients with a history of autoimmune disease such as multiple sclerosis, exclusive of
             a history of thyroiditis, psoriasis, Sjrogen's, or inflammatory bowel disease.

          8. Patients with a history of allergic reactions attributed to compounds used in agent
             preparation.

          9. Patients who are pregnant or breast feeding.

         10. Patient with active or chronic infection of HIV, HCV, or HBV.

         11. Patients who have had a prior LEEP or cervical conization procedure.

         12. History of prior malignancy permitted if patient has been disease free for ≥ 5 years;
             however individuals with completely resected basal cell or squamous cell carcinoma of
             the skin within this interval may be enrolled.

         13. Inability to understand or unwillingness to sign an informed consent document.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients with a cervical cytologic diagnosis of ASC-US or LSIL</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendy Wu, MS</last_name>
    <phone>+886 2 8226 8451</phone>
    <email>wendy@papivax.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yung-Nien Chang, Ph.D.</last_name>
    <phone>410-804-9662</phone>
    <email>changyn@papivax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB | The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nuzhat R Siddiqui, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV16</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atypical Squamous Cells of the Cervix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

